1286 related articles for article (PubMed ID: 31361123)
21. Natural products against key Mycobacterium tuberculosis enzymatic targets: Emerging opportunities for drug discovery.
Cazzaniga G; Mori M; Chiarelli LR; Gelain A; Meneghetti F; Villa S
Eur J Med Chem; 2021 Nov; 224():113732. PubMed ID: 34399099
[TBL] [Abstract][Full Text] [Related]
22. Genetics-directed drug discovery for combating Mycobacterium tuberculosis infection.
Quan Y; Xiong L; Chen J; Zhang HY
J Biomol Struct Dyn; 2017 Feb; 35(3):616-621. PubMed ID: 26900080
[TBL] [Abstract][Full Text] [Related]
23. Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis?
Park HE; Lee W; Shin MK; Shin SJ
Front Immunol; 2021; 12():703060. PubMed ID: 34262571
[TBL] [Abstract][Full Text] [Related]
24. New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics.
Hawn TR; Shah JA; Kalman D
Immunol Rev; 2015 Mar; 264(1):344-62. PubMed ID: 25703571
[TBL] [Abstract][Full Text] [Related]
25. New insights into TB physiology suggest untapped therapeutic opportunities.
Baer CE; Rubin EJ; Sassetti CM
Immunol Rev; 2015 Mar; 264(1):327-43. PubMed ID: 25703570
[TBL] [Abstract][Full Text] [Related]
26. Mycobacterium tuberculosis metabolism.
Warner DF
Cold Spring Harb Perspect Med; 2014 Dec; 5(4):. PubMed ID: 25502746
[TBL] [Abstract][Full Text] [Related]
27. Hit Generation in TB Drug Discovery: From Genome to Granuloma.
Yuan T; Sampson NS
Chem Rev; 2018 Feb; 118(4):1887-1916. PubMed ID: 29384369
[TBL] [Abstract][Full Text] [Related]
28. Current status and future development of antitubercular chemotherapy.
Kremer LS; Besra GS
Expert Opin Investig Drugs; 2002 Aug; 11(8):1033-49. PubMed ID: 12150700
[TBL] [Abstract][Full Text] [Related]
29. New frontiers in the therapy of tuberculosis: fighting with the global menace.
Chhabria M; Jani M; Patel S
Mini Rev Med Chem; 2009 Apr; 9(4):401-30. PubMed ID: 19356120
[TBL] [Abstract][Full Text] [Related]
30. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
[TBL] [Abstract][Full Text] [Related]
31. Priming the tuberculosis drug pipeline: new antimycobacterial targets and agents.
Evans JC; Mizrahi V
Curr Opin Microbiol; 2018 Oct; 45():39-46. PubMed ID: 29482115
[TBL] [Abstract][Full Text] [Related]
32. Development of new antituberculous drugs based on bacterial virulence factors interfering with host cytokine networks.
Tomioka H; Tatano Y; Sano C; Shimizu T
J Infect Chemother; 2011 Jun; 17(3):302-17. PubMed ID: 21243398
[TBL] [Abstract][Full Text] [Related]
33. Isoniazid derivatives and their anti-tubercular activity.
Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
[TBL] [Abstract][Full Text] [Related]
34. Harnessing the mTOR Pathway for Tuberculosis Treatment.
Singh P; Subbian S
Front Microbiol; 2018; 9():70. PubMed ID: 29441052
[TBL] [Abstract][Full Text] [Related]
35. Revolutionizing control strategies against Mycobacterium tuberculosis infection through selected targeting of lipid metabolism.
Kim H; Shin SJ
Cell Mol Life Sci; 2023 Sep; 80(10):291. PubMed ID: 37704889
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in the research of heterocyclic compounds as antitubercular agents.
Yan M; Ma S
ChemMedChem; 2012 Dec; 7(12):2063-75. PubMed ID: 23042656
[TBL] [Abstract][Full Text] [Related]
37. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents.
Keri RS; Sasidhar BS; Nagaraja BM; Santos MA
Eur J Med Chem; 2015 Jul; 100():257-69. PubMed ID: 26112067
[TBL] [Abstract][Full Text] [Related]
38. Allicin enhances antimicrobial activity of macrophages during Mycobacterium tuberculosis infection.
Dwivedi VP; Bhattacharya D; Singh M; Bhaskar A; Kumar S; Fatima S; Sobia P; Kaer LV; Das G
J Ethnopharmacol; 2019 Oct; 243():111634. PubMed ID: 30537531
[TBL] [Abstract][Full Text] [Related]
39. Drug permeation and metabolism in Mycobacterium tuberculosis: Prioritising local exposure as essential criterion in new TB drug development.
Tanner L; Denti P; Wiesner L; Warner DF
IUBMB Life; 2018 Sep; 70(9):926-937. PubMed ID: 29934964
[TBL] [Abstract][Full Text] [Related]
40. Drug discovery in tuberculosis. New drug targets and antimycobacterial agents.
Campaniço A; Moreira R; Lopes F
Eur J Med Chem; 2018 Apr; 150():525-545. PubMed ID: 29549838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
